Cerevel Therapeutics Holdings CERE

$ 44.96 0.0%

Quarterly report 2024-Q1
added 05-08-2024

Cerevel Therapeutics Holdings Balance Sheet 2011-2024 | CERE

Annual Balance Sheet Cerevel Therapeutics Holdings

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-33.6 M	202 M	-161 M	-	-	-	-	-	-3.69 M	-3.34 M	-8.64 M	-20.7 M	-
Long Term Debt	380 M	335 M	34.1 M	-	-	-	-	-	4.4 M	4.28 M	3.82 M	256 K	-
Long Term Debt Current	3.4 M	2.9 M	2.44 M	2.04 M	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	4.4 M	4.28 M	3.82 M	344 K	-
Total Current Liabilities	92.2 M	72.6 M	42.5 M	29.5 M	-	-	-	-	-	-	-	-	-
Total Liabilities	570 M	497 M	110 M	-	-	-	-	-	6.91 M	4.82 M	4.17 M	6.69 M	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	356 K	-	701 K	-
Retained Earnings	-1.4 B	-968 M	-616 M	-	-	-	-	-	-	-	-	-242 M	-
Total Assets	1.24 B	1.02 B	689 M	-	-	-	-	-	1.36 M	3.1 M	4.74 M	69.2 M	-
Cash and Cash Equivalents	416 M	137 M	197 M	388 M	83.7 M	95.4 M	-	-	-	-	-	-	-
Book Value	674 M	521 M	579 M	-	-	-	-	-	-5.55 M	-1.72 M	570 K	62.6 M	-
Total Shareholders Equity	674 M	521 M	579 M	385 M	77.8 M	99.7 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Cerevel Therapeutics Holdings

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	375 M	337 M	380 M	384 M	384 M	335 M	388 M	-	33.4 M	34.1 M	34.8 M	16.1 M	33 M	31 M	31 M	31 M	31 M	25.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	563 M	570 M	549 M	544 M	499 M	497 M	490 M	-	97.1 M	110 M	104 M	97.1 M	68.1 M	60.8 M	60.8 M	60.8 M	60.8 M	43 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.53 B	-1.4 B	-1.27 B	-1.17 B	-1.07 B	-968 M	-875 M	-	-685 M	-616 M	-557 M	-495 M	-442 M	-391 M	-391 M	-391 M	-391 M	-244 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	1.13 B	1.24 B	822 M	894 M	930 M	1.02 B	1.09 B	-	619 M	689 M	733 M	391 M	408 M	445 M	445 M	445 M	445 M	121 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	320 M	416 M	156 M	176 M	154 M	137 M	249 M	138 M	91.8 M	193 M	670 M	327 M	343 M	384 M	384 M	384 M	384 M	79.6 M	-	-	-	95.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	564 M	674 M	273 M	350 M	432 M	521 M	603 M	-	521 M	579 M	629 M	294 M	340 M	385 M	385 M	385 M	385 M	77.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	564 M	674 M	273 M	350 M	432 M	521 M	603 M	453 M	521 M	579 M	629 M	294 M	340 M	385 M	385 M	385 M	385 M	77.8 M	-	-	-	99.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency